Thursday, May 31, 2018

Cancer Gene Therapy - Table of Contents alert Volume 25 Issue 3

If you are unable to see the message below, click here to view.
Cancer Gene Therapy

Volume 25, Issue 3

In this issue
Also new
Nature Outlook: Cancer immunotherapy 

Drugs that mobilize our immune systems against cancer are dramatically improving care for many people, and research is rapidly moving ahead in the lab and the clinic. 

Access this Outlook free >> 

Produced with support from 
F. Hoffmann-La Roche Ltd  

Produced with support of a grant from Merck & Co., Inc.


Potential usefulness of Brevibacillus for bacterial cancer therapy: intratumoral provision of tumor necrosis factor-a and anticancer effects

Hidefumi Mukai, Maiko Takahashi & Yasuyoshi Watanabe

Cancer Gene Therapy 2017 25 :47 - 57; December 18, 2017; 10.1038/s41417-017-0009-7


Abstract | Full Text

Long non-coding RNA DLEU1 predicts poor prognosis of gastric cancer and contributes to cell proliferation by epigenetically suppressing KLF2

Xiaobin Li, Zongze Li, Ziwen Liu, Jianchun Xiao, Shuting Yu et al.

Cancer Gene Therapy 2017 25 :58 - 67; December 27, 2017; 10.1038/s41417-017-0007-9


Abstract | Full Text

miR-200c inhibits TGF-ß-induced-EMT to restore trastuzumab sensitivity by targeting ZEB1 and ZEB2 in gastric cancer

Xinliang Zhou, Xinyi Men, Riyang Zhao, Jing Han, Zhisong Fan et al.

Cancer Gene Therapy 2018 25 :68 - 76; January 04, 2018; 10.1038/s41417-017-0005-y


Abstract | Full Text

Clinical and biological implications of mutational spectrum in acute myeloid leukemia of FAB subtypes M4 and M5

Zhiheng Cheng, Kai Hu, Lei Tian, Yifeng Dai, Yifan Pang et al.

Cancer Gene Therapy 2018 25 :77 - 83; February 28, 2018; 10.1038/s41417-018-0013-6


Abstract | Full Text

Evaluation of FOXC1 as a therapeutic target for basal-like breast cancer

Landon Mott, Kai Su & Daniel W. Pack

Cancer Gene Therapy 2018 25 :84 - 91; March 06, 2018; 10.1038/s41417-018-0010-9


Abstract | Full Text

Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours.

Click here to sign up.
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Cancer Gene Therapy. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: